Aerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from Mizuho

Mizuho reiterated their buy rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research note released on Thursday morning. Mizuho currently has a $87.00 price objective on the stock.

“We do not view quarterly earnings as an important performance measure of companies like Aerie as valuation is primarily driven by progress of the R&D pipeline.”,” the firm’s analyst commented.

A number of other brokerages have also recently weighed in on AERI. Guggenheim began coverage on shares of Aerie Pharmaceuticals in a research report on Monday, October 23rd. They set a buy rating and a $80.00 price target for the company. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 24th. Canaccord Genuity reiterated a positive rating and set a $73.00 price target (up from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Needham & Company LLC reiterated a buy rating and set a $76.00 price target (up from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Finally, BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $70.93.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded up $0.25 on Thursday, hitting $62.00. 324,800 shares of the company’s stock were exchanged, compared to its average volume of 512,286. Aerie Pharmaceuticals has a 1-year low of $35.20 and a 1-year high of $66.25. The company has a quick ratio of 22.45, a current ratio of 22.44 and a debt-to-equity ratio of 0.67.

COPYRIGHT VIOLATION NOTICE: “Aerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from Mizuho” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/aerie-pharmaceuticals-inc-aeri-earns-buy-rating-from-mizuho.html.

Several hedge funds have recently made changes to their positions in AERI. Ameritas Investment Partners Inc. grew its holdings in shares of Aerie Pharmaceuticals by 11.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after purchasing an additional 275 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of Aerie Pharmaceuticals by 792.5% in the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after purchasing an additional 2,647 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Aerie Pharmaceuticals by 2,711.4% in the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after purchasing an additional 3,579 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Aerie Pharmaceuticals in the second quarter valued at approximately $204,000. Finally, Great West Life Assurance Co. Can grew its holdings in shares of Aerie Pharmaceuticals by 65.0% in the third quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock valued at $204,000 after purchasing an additional 1,639 shares in the last quarter. Hedge funds and other institutional investors own 94.67% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply